Actively Recruiting
Assessment of Liver Health Using Dual Cholate Clearance Assay in Adults with Fontan-Associated Liver Disease and Heart Failure
Led by HepQuant, LLC · Updated on 2026-09-17
75
Participants Needed
1
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to understand liver function in adults with Fontan-associated liver disease FALD by using the HepQuant dual cholate clearance assay, which measures liver function in people with chronic liver conditions. The study compares liver function and blood flow in Fontan patients, patients with right heart failure RHF, and healthy individuals. It also evaluates whether cholate clearance can predict clinical outcomes in these populations. Participants will undergo a dual cholate clearance assay involving oral and intravenous labeled cholate followed by blood samples over 60 minutes to measure serum cholate levels. They will also have a non-contrast cardiac magnetic resonance imaging MRI scan without sedation at the start of the study. The groups include adults with Fontan circulation who had recent right heart catheterization, adults with RHF and specific heart function criteria, and healthy controls with normal heart anatomy and function. Throughout the study, participants health status will be monitored and data collected for five years following the initial tests. The primary measure is hepatic cholate clearance at baseline, and secondary outcomes include the occurrence of heart or liver-related clinical events over the five-year follow-up. This long-term observation helps researchers understand liver health and disease progression in these groups.
CONDITIONS
Brief Title
Cholate Clearance in Fontan and Heart Failure
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here